If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

11 Aug 2021 11:30

RNS Number : 3165I
Amryt Pharma PLC
11 August 2021
 

 

 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are at- tachedii:

 

Amryt Pharma PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

 

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

X

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

EdgePoint Investment Group Inc.

City and country of registered office (if applicable)

Toronto, Canada

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

06/08/2021

6. Date on which issuer notified (DD/MM/YYYY):

10/08/2021

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights at- tached to shares (to- tal of 8. A)

% of voting rights through financial in- struments

(total of 8.B 1 + 8.B 2)

 

Total of both in % (8.A + 8.B)

Total number of voting rights of is- suervii

Resulting situation on the date on which

threshold was crossed or reached

 

0%

 

3.71%

 

3.71%

 

307,118,662

Position of previous notification (if applicable)

 

0%

 

7.93%

 

7.93%

 

       

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

 

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

 

Type of financial in- strument

 

Expiration datex

 

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

 

% of voting rights

ADSs US03217L1061

N/A

N/A

11,389,820

3.71%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

11,389,820

3.71%

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration datex

Exercise/

Conversion Pe- riod xi

Physical or

cash settlementxii

Number of voting rights

 

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

          
 

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

X

 

 

Namexv

% of voting rights if it equals or is higher than the notifiable

threshold

% of voting rights through financial in- struments if it equals or is higher than the

notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

EdgePoint Investment Group Inc.

 

 

 

EdgePoint Wealth Manage- ment Inc.

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

 

11. Additional informationxvi

Full chain of controlled undertakings:

 

EdgePoint Investment Group Inc. EdgePoint Wealth Management Inc.

     

 

Place of completion

Toronto, Canada

Date of completion

10/08/2021

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBFLFFFVLLBBK
Date   Source Headline
19th Feb 202012:00 pmRNSDraft registration statement for US Nasdaq listing
15th Jan 20205:16 pmRNSHolding(s) in Company
15th Jan 20207:00 amRNSAmryt to present updates from its EB research
7th Jan 202012:09 pmRNSPDMR Dealings
30th Dec 201911:07 amRNSHolding(s) in Company
27th Dec 20198:00 amRNSEuronext Growth Dublin Notice
23rd Dec 201911:22 amRNSHolding(s) in Company
20th Dec 20192:40 pmRNSExercise of Warrants & Issue of Ordinary Shares
19th Dec 20197:00 amRNSBusiness integration and synergies on track
26th Nov 20197:00 amRNSHoldings in Company
18th Nov 20197:00 amRNSHoldings in Company
14th Nov 20194:31 pmRNSShare Buyback
5th Nov 20196:16 pmRNSGrant of Options
5th Nov 20197:00 amRNSTrading Update
4th Nov 20197:00 amRNSNotice of Trading Update
28th Oct 20194:58 pmRNSHolding(s) in Company
3rd Oct 20194:38 pmRNSHoldings in Company
1st Oct 20197:00 amRNSAP101 Receives Fast Track Designation from FDA
30th Sep 20194:30 pmRNSHalf-year Report
30th Sep 20197:00 amRNSInvestor Events Update
30th Sep 20197:00 amRNSHolding(s) in Company
25th Sep 20197:00 amRNSCompletion of Acquisition and $60m equity raised
24th Sep 201912:30 pmRNSSchedule One Update - Amryt Pharma Plc
24th Sep 20198:29 amRNSSchedule One Update
24th Sep 20197:30 amRNSSuspension - Amryt Pharma Plc
23rd Sep 20192:15 pmRNSCourt Sanction of the Scheme of Arrangement
20th Sep 20198:00 amRNSEuronext Growth Dublin Notice
19th Sep 20191:30 pmRNSResults of Court Meeting and General Meeting
13th Sep 20197:00 amRNSCircular to Shareholders
11th Sep 20193:00 pmRNSUpdate on Acquisition of Aegerion
5th Sep 20192:30 pmRNSSchedule One - Amryt Pharma plc
5th Sep 20192:30 pmRNSSchedule One
4th Sep 20198:00 amRNSEuronext Growth Dublin Suspension Notice
4th Sep 20197:00 amRNSSuspension of Trading on Euronext
3rd Sep 20191:00 pmRNSHoldings in Company
30th Aug 20193:06 pmRNSHolding(s) in Company
30th Aug 20198:00 amRNSEuronext Growth Dublin Notice
30th Aug 20197:00 amRNSDirector/PDMR Shareholding
27th Aug 20191:00 pmRNSEuronext Growth Dublin Restoration Notice
27th Aug 20191:00 pmRNSRestoration - Amryt Pharma Plc
27th Aug 20191:00 pmRNSPublication of Admission Document and Circular
10th Jul 201911:23 amRNSResult of AGM
12th Jun 20197:00 amRNSPosting of Annual Report and Notice of AGM
22nd May 20196:24 pmRNSGrant of Options
21st May 20197:30 amRNSEuronext Growth Dublin Suspension Notice
21st May 20197:30 amRNSSuspension - Amryt Pharma plc
21st May 20197:00 amRNSRecommended Acquisition of Aegerion
17th Apr 20197:00 amRNSPreliminary Results and Q1 Trading Update
12th Apr 201910:04 amRNSNotice of Results
28th Feb 20197:00 amRNSUpdate on AP101 EASE Phase III trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.